Addex Therapeutics (ADXN) Other Non-Current Assets (2018 - 2025)
Addex Therapeutics (ADXN) posted Other Non-Current Assets of $8865.8 for Q4 2025, up 3.58% sequentially from $8559.1 in Q2 2025, and up 9.56% YoY from $8092.2 in Q4 2024.
Addex Therapeutics (ADXN) Other Non-Current Assets (2018 - 2025) Analysis & Trends
Addex Therapeutics has reported Other Non-Current Assets for 8 years, with the latest figure at $8865.8 in Q4 2025.
- Quarterly Other Non-Current Assets rose 9.56% year-over-year to $8865.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8865.8 (up 9.56% YoY) and the FY2025 annual result came in at $8546.6, up 6.06% from the prior year.
- Other Non-Current Assets climbed to $8865.8 in Q4 2025 per ADXN's latest filing, from $8559.1 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $904951.5 in Q1 2024 and troughed at $8092.2 in Q4 2024.
- A 5-year average of $136855.8 and a median of $60298.9 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets slumped 86.79% in 2024, then grew 9.56% in 2025.
- Over 5 years, Other Non-Current Assets stood at $62801.3 in 2021, then slipped by 10.16% to $56421.7 in 2022, then advanced by 8.58% to $61265.0 in 2023, then plunged by 86.79% to $8092.2 in 2024, then rose by 9.56% to $8865.8 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $8865.8, $8559.1, and $8092.2 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8,865.79 |
| Jun 30, 2025 | 8,559.11 |
| Dec 31, 2024 | 8,092.25 |
| Mar 31, 2024 | 904,951.55 |
| Dec 31, 2023 | 61,264.95 |
| Jun 30, 2023 | 60,446.74 |
| Dec 31, 2022 | 56,421.68 |
| Jun 30, 2022 | 60,298.87 |
| Dec 31, 2021 | 62,801.35 |
| Dec 31, 2020 | 65,422.47 |
| Dec 31, 2019 | 69,626.55 |
| Dec 31, 2018 | 54,667.03 |